Global Breast Lumpectomy Treatment Market
Global Breast Lumpectomy Treatment Market

Breast Lumpectomy Treatment Comprehensive Study by Treatment (Stage I Breast Cancer, Stage II Breast Cancer, DCIS (Ductal Carcinoma in Situ)), End User (Research Institutes and Academic Centers, Hospitals, Specialized Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2025

Breast Lumpectomy Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 232 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Breast Lumpectomy Treatment Market Overview:
Breast lumpectomy treatment is a surgery in which only the part of the breast containing the cancer is removed. The goal is to remove cancer as well as some surrounding normal tissue. How much breast is removed depends on where and how big the tumor is, as well as other factors. The growing patient population comprises an estimated 15% of women with breast cancer that has led to significant growth in the breast lumpectomy treatment market in the forecast period.

Growth Drivers
  • Rising Incidence of Breast Cancer across the Globe
  • Increasing Healthcare Expenditure by Various Countries

Market Trends
  • Rising Chronic Diseases such as Cancer

Roadblocks
  • Lack of Treatment Centers

Opportunities
  • Technology Advancements and Development in leading to Better Imaging in Treatment of Breast Cancer

Challenges
  • Various Side Effect during Treatment


Competitive Landscape:

Some of the key players profiled in the report are Memorial Sloan Kettering Cancer Center (United States), Susan G Komen (United States), American Cancer Society, Inc (United States), Mayo Foundation for Medical Education and Research (United States), Moffitt Cancer Center (United States), Cedars-Sinai (United States), Breast Cancer Network Australia (Australia), The University of Texas MD Anderson Cancer Center (United States), Mount Elizabeth Hospital (Singapore) and Carl Zeiss AG (Germany). Additionally, following companies can also be profiled that are part of our coverage like Cianna Medical (United States), Dune Medical Devices (United States), Hologic (United States) and Medtronic (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Breast Lumpectomy Treatment market by 2025. Considering Market by Treatment, the sub-segment i.e. Stage I Breast Cancer will boost the Breast Lumpectomy Treatment market. Considering Market by End User, the sub-segment i.e. Research Institutes and Academic Centers will boost the Breast Lumpectomy Treatment market.

Breast cancer surgery is a key component of breast cancer treatment that involves removing cancer with an operation. The surgery may be used alone or in combination with other treatments, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Breast Lumpectomy Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Breast Lumpectomy Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Breast Lumpectomy Treatment Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Treatment
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • DCIS (Ductal Carcinoma in Situ)

By End User
  • Research Institutes and Academic Centers
  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Breast Cancer across the Globe
      • 3.2.2. Increasing Healthcare Expenditure by Various Countries
    • 3.3. Market Challenges
      • 3.3.1. Various Side Effect during Treatment
    • 3.4. Market Trends
      • 3.4.1. Rising Chronic Diseases such as Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Lumpectomy Treatment, by Treatment, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Breast Lumpectomy Treatment (Value)
      • 5.2.1. Global Breast Lumpectomy Treatment by: Treatment (Value)
        • 5.2.1.1. Stage I Breast Cancer
        • 5.2.1.2. Stage II Breast Cancer
        • 5.2.1.3. DCIS (Ductal Carcinoma in Situ)
      • 5.2.2. Global Breast Lumpectomy Treatment by: End User (Value)
        • 5.2.2.1. Research Institutes and Academic Centers
        • 5.2.2.2. Hospitals
        • 5.2.2.3. Specialized Clinics
        • 5.2.2.4. Ambulatory Surgical Centers
      • 5.2.3. Global Breast Lumpectomy Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Breast Lumpectomy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Memorial Sloan Kettering Cancer Center (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Susan G Komen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. American Cancer Society, Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mayo Foundation for Medical Education and Research (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Moffitt Cancer Center (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cedars-Sinai (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Breast Cancer Network Australia (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. The University of Texas MD Anderson Cancer Center (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mount Elizabeth Hospital (Singapore)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Carl Zeiss AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Lumpectomy Treatment Sale, by Treatment, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Breast Lumpectomy Treatment (Value)
      • 7.2.1. Global Breast Lumpectomy Treatment by: Treatment (Value)
        • 7.2.1.1. Stage I Breast Cancer
        • 7.2.1.2. Stage II Breast Cancer
        • 7.2.1.3. DCIS (Ductal Carcinoma in Situ)
      • 7.2.2. Global Breast Lumpectomy Treatment by: End User (Value)
        • 7.2.2.1. Research Institutes and Academic Centers
        • 7.2.2.2. Hospitals
        • 7.2.2.3. Specialized Clinics
        • 7.2.2.4. Ambulatory Surgical Centers
      • 7.2.3. Global Breast Lumpectomy Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Lumpectomy Treatment: by Treatment(USD Million)
  • Table 2. Breast Lumpectomy Treatment Stage I Breast Cancer , by Region USD Million (2014-2019)
  • Table 3. Breast Lumpectomy Treatment Stage II Breast Cancer , by Region USD Million (2014-2019)
  • Table 4. Breast Lumpectomy Treatment DCIS (Ductal Carcinoma in Situ) , by Region USD Million (2014-2019)
  • Table 5. Breast Lumpectomy Treatment: by End User(USD Million)
  • Table 6. Breast Lumpectomy Treatment Research Institutes and Academic Centers , by Region USD Million (2014-2019)
  • Table 7. Breast Lumpectomy Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 8. Breast Lumpectomy Treatment Specialized Clinics , by Region USD Million (2014-2019)
  • Table 9. Breast Lumpectomy Treatment Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 10. South America Breast Lumpectomy Treatment, by Country USD Million (2014-2019)
  • Table 11. South America Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 12. South America Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 13. Brazil Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 14. Brazil Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 15. Argentina Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 16. Argentina Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 17. Rest of South America Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 18. Rest of South America Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 19. Asia Pacific Breast Lumpectomy Treatment, by Country USD Million (2014-2019)
  • Table 20. Asia Pacific Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 21. Asia Pacific Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 22. China Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 23. China Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 24. Japan Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 25. Japan Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 26. India Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 27. India Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 28. South Korea Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 29. South Korea Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 30. Taiwan Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 31. Taiwan Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 32. Australia Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 33. Australia Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 34. Rest of Asia-Pacific Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 35. Rest of Asia-Pacific Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 36. Europe Breast Lumpectomy Treatment, by Country USD Million (2014-2019)
  • Table 37. Europe Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 38. Europe Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 39. Germany Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 40. Germany Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 41. France Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 42. France Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 43. Italy Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 44. Italy Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 45. United Kingdom Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 46. United Kingdom Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 47. Netherlands Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 48. Netherlands Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 49. Rest of Europe Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 50. Rest of Europe Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 51. MEA Breast Lumpectomy Treatment, by Country USD Million (2014-2019)
  • Table 52. MEA Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 53. MEA Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 54. Middle East Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 55. Middle East Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 56. Africa Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 57. Africa Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 58. North America Breast Lumpectomy Treatment, by Country USD Million (2014-2019)
  • Table 59. North America Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 60. North America Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 61. United States Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 62. United States Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 63. Canada Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 64. Canada Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 65. Mexico Breast Lumpectomy Treatment, by Treatment USD Million (2014-2019)
  • Table 66. Mexico Breast Lumpectomy Treatment, by End User USD Million (2014-2019)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Breast Lumpectomy Treatment: by Treatment(USD Million)
  • Table 78. Breast Lumpectomy Treatment Stage I Breast Cancer , by Region USD Million (2020-2025)
  • Table 79. Breast Lumpectomy Treatment Stage II Breast Cancer , by Region USD Million (2020-2025)
  • Table 80. Breast Lumpectomy Treatment DCIS (Ductal Carcinoma in Situ) , by Region USD Million (2020-2025)
  • Table 81. Breast Lumpectomy Treatment: by End User(USD Million)
  • Table 82. Breast Lumpectomy Treatment Research Institutes and Academic Centers , by Region USD Million (2020-2025)
  • Table 83. Breast Lumpectomy Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 84. Breast Lumpectomy Treatment Specialized Clinics , by Region USD Million (2020-2025)
  • Table 85. Breast Lumpectomy Treatment Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 86. South America Breast Lumpectomy Treatment, by Country USD Million (2020-2025)
  • Table 87. South America Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 88. South America Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 89. Brazil Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 90. Brazil Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 91. Argentina Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 92. Argentina Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 93. Rest of South America Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 94. Rest of South America Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 95. Asia Pacific Breast Lumpectomy Treatment, by Country USD Million (2020-2025)
  • Table 96. Asia Pacific Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 97. Asia Pacific Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 98. China Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 99. China Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 100. Japan Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 101. Japan Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 102. India Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 103. India Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 104. South Korea Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 105. South Korea Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 106. Taiwan Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 107. Taiwan Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 108. Australia Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 109. Australia Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 110. Rest of Asia-Pacific Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 111. Rest of Asia-Pacific Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 112. Europe Breast Lumpectomy Treatment, by Country USD Million (2020-2025)
  • Table 113. Europe Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 114. Europe Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 115. Germany Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 116. Germany Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 117. France Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 118. France Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 119. Italy Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 120. Italy Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 121. United Kingdom Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 122. United Kingdom Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 123. Netherlands Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 124. Netherlands Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 125. Rest of Europe Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 126. Rest of Europe Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 127. MEA Breast Lumpectomy Treatment, by Country USD Million (2020-2025)
  • Table 128. MEA Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 129. MEA Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 130. Middle East Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 131. Middle East Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 132. Africa Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 133. Africa Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 134. North America Breast Lumpectomy Treatment, by Country USD Million (2020-2025)
  • Table 135. North America Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 136. North America Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 137. United States Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 138. United States Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 139. Canada Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 140. Canada Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 141. Mexico Breast Lumpectomy Treatment, by Treatment USD Million (2020-2025)
  • Table 142. Mexico Breast Lumpectomy Treatment, by End User USD Million (2020-2025)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Lumpectomy Treatment: by Treatment USD Million (2014-2019)
  • Figure 5. Global Breast Lumpectomy Treatment: by End User USD Million (2014-2019)
  • Figure 6. South America Breast Lumpectomy Treatment Share (%), by Country
  • Figure 7. Asia Pacific Breast Lumpectomy Treatment Share (%), by Country
  • Figure 8. Europe Breast Lumpectomy Treatment Share (%), by Country
  • Figure 9. MEA Breast Lumpectomy Treatment Share (%), by Country
  • Figure 10. North America Breast Lumpectomy Treatment Share (%), by Country
  • Figure 11. Global Breast Lumpectomy Treatment share by Players 2019 (%)
  • Figure 12. Global Breast Lumpectomy Treatment share by Players (Top 3) 2019(%)
  • Figure 13. Global Breast Lumpectomy Treatment share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Memorial Sloan Kettering Cancer Center (United States) Revenue, Net Income and Gross profit
  • Figure 16. Memorial Sloan Kettering Cancer Center (United States) Revenue: by Geography 2019
  • Figure 17. Susan G Komen (United States) Revenue, Net Income and Gross profit
  • Figure 18. Susan G Komen (United States) Revenue: by Geography 2019
  • Figure 19. American Cancer Society, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. American Cancer Society, Inc (United States) Revenue: by Geography 2019
  • Figure 21. Mayo Foundation for Medical Education and Research (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mayo Foundation for Medical Education and Research (United States) Revenue: by Geography 2019
  • Figure 23. Moffitt Cancer Center (United States) Revenue, Net Income and Gross profit
  • Figure 24. Moffitt Cancer Center (United States) Revenue: by Geography 2019
  • Figure 25. Cedars-Sinai (United States) Revenue, Net Income and Gross profit
  • Figure 26. Cedars-Sinai (United States) Revenue: by Geography 2019
  • Figure 27. Breast Cancer Network Australia (Australia) Revenue, Net Income and Gross profit
  • Figure 28. Breast Cancer Network Australia (Australia) Revenue: by Geography 2019
  • Figure 29. The University of Texas MD Anderson Cancer Center (United States) Revenue, Net Income and Gross profit
  • Figure 30. The University of Texas MD Anderson Cancer Center (United States) Revenue: by Geography 2019
  • Figure 31. Mount Elizabeth Hospital (Singapore) Revenue, Net Income and Gross profit
  • Figure 32. Mount Elizabeth Hospital (Singapore) Revenue: by Geography 2019
  • Figure 33. Carl Zeiss AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Carl Zeiss AG (Germany) Revenue: by Geography 2019
  • Figure 35. Global Breast Lumpectomy Treatment: by Treatment USD Million (2020-2025)
  • Figure 36. Global Breast Lumpectomy Treatment: by End User USD Million (2020-2025)
  • Figure 37. South America Breast Lumpectomy Treatment Share (%), by Country
  • Figure 38. Asia Pacific Breast Lumpectomy Treatment Share (%), by Country
  • Figure 39. Europe Breast Lumpectomy Treatment Share (%), by Country
  • Figure 40. MEA Breast Lumpectomy Treatment Share (%), by Country
  • Figure 41. North America Breast Lumpectomy Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Memorial Sloan Kettering Cancer Center (United States)
  • Susan G Komen (United States)
  • American Cancer Society, Inc (United States)
  • Mayo Foundation for Medical Education and Research (United States)
  • Moffitt Cancer Center (United States)
  • Cedars-Sinai (United States)
  • Breast Cancer Network Australia (Australia)
  • The University of Texas MD Anderson Cancer Center (United States)
  • Mount Elizabeth Hospital (Singapore)
  • Carl Zeiss AG (Germany)
Additional players considered in the study are as follows:
Cianna Medical (United States) , Dune Medical Devices (United States) , Hologic (United States) , Medtronic (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation